The Challenge of Change - Managing Excipients Control
Colorcon
| « Previous month | Next month » |
Crucell and DSM will further expand the development of its PER.C6 protein and monoclonal antibody licensing business by establishing joint R&D centres on the US East Coast and in the Netherlands.
A vibrating disc could have uses in laboratory diagnosis by identifying and monitoring common types of cancer, providing specialists with information about the most appropriate therapeutic strategy.
Fisher Biosciences's HyClone business has partnered with Alfa Laval to provide disposable bioprocessing systems for Haemacure's new manufacturing facility for biological adhesives - one of the first major installations of this technology for large-scale bioprocessing.
US scientists think that enough anthrax vaccine can be produced cheaply and effectively from tobacco plants, inoculating not only the whole of the US but answer the worldwide need for a safe and effective vaccine for this killer toxin.
Silicones are fuelling innovations in topical drug excipients, due to their unique set of physicochemical properties that improve active pharmaceutical ingredient (API) delivery and ease of product application.
Actors have their Oscars and musicians have their Grammy awards and the pharmaceutical industry is increasingly trying to recognise the achievements of its high fliers.
A new robotic system, which provides data for genetic engineering, provides an additional method in rapid mass screening to identify new species as pharma becomes more open to using microorganisms as living factories for producing drugs and biochemical products.
In the same week that saw Novartis threaten its planned merger with Berna Biotech, Dutch biotech company Crucell has signed three new licensing agreements for its PER.C6 and STAR manufacturing technologies.
Bristol-Myers Squibb (BMS) has cut $400 million in annual expenses over the last two years in order to boost its R&D pipeline and achieve sales and earnings growth beginning in 2007.
Actavis Group has announced the company has acquired the human generics business of Alpharma, making the international generic pharmaceuticals company one of the five largest companies in generic pharmaceuticals worldwide in terms of revenue.
Scientists have described the cellular structure of a protein that plays a critical role in drug resistance, which may open up new avenues for laboratory research that may result in the enhancement of existing therapies for Cancer and infectious diseases.
Fine chemical and pharmaceutical intermediate manufacturers may be affected by supply disruptions due to ongoing UK shortages of natural gas. Price spikes in gas are becoming both higher and more frequent in the UK.
DOV Pharmaceutical has announced the initiation of a Phase Ib clinical trial, which investigates the potential of its triple reuptake inhibitor candidate for treating depression. The drug's mechanism of action inhibits three separate neurotransmitters serotonin, norepinephrine and dopamine.
Cambridge Biostability Limited (CBL) has commissioned the world's first commercial sterile spray dryer for childhood vaccines, in which the £1 million (€1.5 million) facility will produce clinical trial material providing a precursor for further large-scale stable vaccine production.
The European Commission has profiled the top 100 biotech technology offers in a new brochure, which showcases the offers in such a way that encourages European researchers to pursue the exploitation of their own research results.
India's Ranbaxy Laboratories has been granted a US patent on its controlled-release drug delivery system, which takes the form of a 'floating' tablet that once swallowed, is retained in the upper gastrointestinal tract to provide maximum drug absorption.
Budding biotech company Artelis is the first to benefit from Solvay's new strategy to undertake 50 per cent of its new projects in partnership with outside start-up companies.
Merck & Co said it would cut an additional $1 billion (€832 million) through 2010 as it struggles to regain R&D momentum after mounting lawsuits, generic competition and falling revenue and profit threaten to engulf the company, shifting the focus away from its research on medicines for cancer and Alzheimer's.
Scientists have found a new way to sneak drugs past the blood-brain barrier by using stem cell derived brain cells to deliver a critical growth factor that has already shown clinical promise for treating Parkinson's disease.
The first single laboratory platform for 3D imaging and metrology of microfluidic devices has been made available, which allows for the characterisation of subsurface structure in transparent media with submicron accuracy.
Patheon has resumed normal production of Omnicef antibiotic powder after it voluntarily suspended production in September at it facility in Carolina, Puerto Rico, due to a US Food and Drug Administration (FDA) manufacturing warning.
Johns Hopkins researchers have devised a self-assembling cube-shaped perforated container, which may serve as a delivery system for medications and cell therapy that can easily be tracked via MRI.
Degussa is streamlining its organization and decreasing the number of business units from 20 to 17, in order to compete in the global markets and be in a better position to exploit growth opportunities.
Superfos Pharma, one of Europe's leading suppliers of plastic packaging for the pharma market, has been acquired by Gerresheimer in a move that should double the group's turnover in plastics to €50 million.
New insights into the dysregulation of beta cells and their impact on type 2 diabetes progression is now possible after Roche announced a partnership, which aims to identify novel pathways and new biomarkers for drug development.
EU ministers yesterday agreed on a compromise version of the controversial new chemicals law, REACH, however environment groups have condemned the latest changes as a further watering down of the law in favour of industry.
A toxicology-on-a-chip tool, which can analyse drug candidates for toxicity before they advance to pre-clinical stages, has taken one step further towards commercialisation as the technology promises to aid laboratory researchers in weeding out unsuitable candidates earlier during the drug discovery process.
SciGen are to establish a manufacturing facility in China in a response to the growing demand for the Hepatitis B (HBV) vaccine and insulin, which has reached epidemic proportions with 2 billion people having become infected with HBV at some time in their lives.
Drug production company Patheon has released its fourth-quarter results, which has revealed that profit has jumped 180 per cent despite a recent production halt at a Puerto Rican subsidiary. This bodes well for the recent manufacturing and drug development (PDS) service strategy in both North America and Europe.
GlaxoSmithKline (GSK) has positioned itself to dominate the US flu vaccine market after it completed the acquisition of Canadian vaccine company ID Biomedical for $1.7 billion (€1.15 billion) last week.
US drug company, Eli Lilly, offered a more encouraging outlook than was expected forecasting an earnings growth of up to 12 per cent, a stark contrast to its struggling competitors, who also face generic competition, drug safety and regulation.
US drug company, Eli Lilly, offered a more encouraging outlook than was expected forecasting an earnings growth of up to 12 per cent, a stark contrast to its struggling competitors, who also face generic competition, drug safety and regulation.
Roche has responded to recent criticism that it was protecting its avian-flu formula too closely by identifying 12 prospective partners to increase the global production of Tamiflu.
UK drug development company SkyePharma, which put itself up for sale last month, has said that several new bidders have expressed interest in buying some of its assets as well as acquiring the entire company for cash.
Biovest International used the Cancer Research Institute's recent meeting to debut its newest cell culture instrument, the AutovaxID-C, which represents an advance in personalised medicine, reducing the possibility of cross contamination, allowing segregation of patient specific vaccine batches.
SR Pharma, specializing in RNAi therapeutics, will be the first company to use the new UK National Biomanufacturing Centre (NBC), operated by contract manufacturing organization (CMO) Eden Biodesign, when it opens on schedule early next year.
The world's first transdermal patch for the treatment of Alzheimer's disease (AD) will offer patients an improved treatment delivery choice and could lead to more patients taking their medication.
Generex Biotechnology announced its Oral-lyn, the first non-injectable form of recombinant human insulin available for commercial distribution anywhere in the world is being launched in Ecuador to soon become available through physician referrals.
Innovata has entered into a second agreement in which the development of a combination asthma therapy could generate in excess of £25 million (€37 million) in milestones and development funding.
CombiMatrix Molecular Diagnostics (CMD) are to collaborate with the University Of California (UCLA), on a gene-based melanoma laboratory test, which if successful, could result in the development of a clinical molecular test that will more accurately diagnose melanoma, improving patient outcomes.
Samson Medical Technologies has signed a co-marketing agreement with Baxa for its novel packaging system designed to improve patient safety by reducing the risk of medication errors in prescription drug compounding.
UK's MedPharm has received a Department of Trade and Industry (DTI) grant for Research and Development to produce its new spray treatment for eczema, expected to be available in the US by 2009.
Pharmaceutical companies and manufacturers are increasingly moving to adopt software services that prevent revenue leakage and regulatory compliance exposure.
Phoqus has announced it has commenced Phase I of a clinical study researching its experimental treatment, which could become the first Circadian endocrine treatment for adrenal insufficiency.
Filtration system Pall Corporation reported its first quarter earnings which revealed earnings rose by 16 per cent, propelled by growth in its industrial and biopharmaceuticals segments.
Invitrogen has created three new business divisions in a move to strengthen its position in the growing biotechnology industry and drive growth through improving links between its product development cycle and customer base.
According to a new report, the demand for worldwide drug packaging is expected to reach new heights, predicting growth of 5.3 per cent annually to $24.3 billion (€20 7 billion) in 2009, driven by aging demographic patterns increasing disease incidences.
A new algorithm, which automatically selects molecule images for crystallisation in Silico studies, is set to advance laboratory studies by increasing the speed and power of methods for determining biological structures at high resolution, based on data from electron microscopy.
After a two-year tug-of-war, the World Trade Organization (WTO) has solidified a landmark agreement to allow poor nations to import generic versions of patented drugs to treat serious diseases or epidemics.
Astech have launched its new automated tablet processing system for drug content analysis, set to increase manufacturing quality control efficiency by 100 per cent.
Domantis has announced an alliance with pharma giants Bristol-Myers Squibb to develop human Domain Antibody (dAb) products, a novel approach to address therapeutic targets involved in T-cell co-stimulation.
Aegate will launch a software solution to combat one of the pharmaceutical industry's biggest and growing patient safety issues - counterfeit drugs - in the UK, US and Belgium in 2006 following the recent success of its UK pilot programme.
Grunenthal has developed a novel method of delivering drugs to children in the form of a drinking straw, which is set to provide a solution to administering treatment to patients who cannot tolerate unpleasant tasting drugs.
Baxa Corporation launches its medication validation system that validates narcotic returns and identifies counterfeit medications. The system also offers validation of medication to ensure the type and strength of high-risk medications.
BASF has announced that it is to raise prices of its pharmaceutical excipients in a move that represents the wider market that has seen big cost increases for raw materials, energy and transportation that has affected all excipient manufacturers.
Clinical trials service provider, The Specials Clinical Manufacturing, has announced the recent installation of Isopak's In-Cap machine, an automatic bench machine that is currently the smallest automatic filling machine in the world.
Carrington Laboratories has been granted a European patent for its drug and vaccine delivery technology, representing the first European Patent issued for the company's GelSite Polymer, designed for peptide and protein-based drugs.
A novel drug delivery system that allows hospital patients to self-administer pain relief medication without an intravenous line could be available in the US within six months, pending final Food and Drug Administration (FDA) approval.
Omron Corp aims to invest $20 million in the next two years in an attempt to capture a larger slice of the RFID market, which is expected to swell from $1.95 billion (€1.65 million) in 2005 to an estimated $26.9 billion in 2015, driven by cost competitive technology.
Laboratory researchers believe that a recent discovery will prove highly effective in stopping the progress of anthrax infection, further developing reliable treatments to diagnose this killer microorganism.
A Strategic Research Agenda (SRA) was launched last week in a move to bolster the chemistry and biotechnology industry's contribution to European growth and competitiveness.
Escalating drug costs could be driven down by up to $20 billion a year and dwindling drug pipelines improved if a newly-formed US research group is successful.
| « Previous month | Next month » |